Диссертация (1141255), страница 29
Текст из файла (страница 29)
– Vol.19 – № 3. – P. 115–116120.Lai, C.K. Global variation in the prevalence and severity of asthmasymptoms: Phase Three of the International Study of Asthma and Allergies in185Childhood (ISAAC) / C.K. Lai [et al.]. // Thorax. – 2009. – Vol. 64. – № 6. – P.476-483.121.Laube, B.L. What the pulmonary specialist should know about the newinhalation therapies / B.L. Laube [et al.]. // Eur Respir J. – 2011. – №6. – P. 1308-1331.122.List of national competent authorities in the EEA: European MedicinesAgency[Electronicresource].http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_000155.jsp&mid=WC0b01ac0580036d63 (access date: 22.05.2018).123.Lloyd, A.
The impact of asthma exacerbations on health-related quality oflife in moderate to severe asthma patients in the UK / A. Lloyd, D. Price, R. Brown// Prim. Care Respir. J. – 2007. – Vol. 16. – № 1. – P. 22-27.124.Makarova, E. Budget impact analysis of same and mixed budesonide andformoterol inhalers in the treatment of asthma in Russian federation / E. Makarova,R. Yagudina, A. Kulikov // Value in Health – 2017. – Vol. 20 – № 9 – P.
641.125.Makarova, E. Comparison of budesonide inhalers for treatment of asthma inadults and adolescents in Russian Federation: cost – effectiveness analysis / Makarova,R. Yagudina, A. Kulikov // Value in Health – 2017. – Vol. 20 – № 9 – P. 646126.Makarova, E. Cost–utility analysis of two budesonide inhalers for treatmentof asthma in children in Russian Federation / E.
Makarova, R. Yagudina, A.Kulikov // Value in Health – 2017. – Vol. 20 – № 9 – P. 646-A647.127.Makarova, E. The impact of inhaler device choice for the effectiveness of asthmatreatment: the pharmacoeconomic evaluation / E. Makarova // SCIENCE4HEALTH2018. Клинические и теоретические аспекты современной медицины: материалыIХ Международной научной конференции. Москва, РУДН, 24–28 апреля 2018 г.– М.: РУДН, 2018. – С. 164.128.McTaggart-Cowan, H.M. The validity of generic and condition-specificpreference-based instruments: the ability to discriminate asthma control status. /H.M.
McTaggart-Cowan // Qual Life Res. – 2008. – Vol. 17 – № 3 – P. 453-462.129.Melani, A.S. Inhaler mishandling remains common in real life and isassociated with reduced disease control / A.S Melani [et al.] // Respir. Med. – 2011.186– Vol. 105. – № 6. – P. 930-938.130.Mittmann, N. Health utility attributes for chronic conditions / N. Mittmann[et al.] // Dis. Manag. Heal. Outcomes. – 2001. – Vol. 9. – №1.
– P. 11-21.131.Mittmann, N. Utility scores for chronic conditions in a community-dwellingpopulation / N. Mittmann [et al.] // Pharmacoeconomics. – 1999. – Vol. 15. – № 4.– P. 369-376.132.Moy, M.L. Association between preference-based health-related quality oflife and asthma severity / M.L. Moy [et al.] // Ann.
Allergy, Asthma Immunol. –2004. – Vol. 92. – № 3. – P. 329-334.133.Norman, G. Omalizumab for the treatment of severe persistent allergicasthma: a systematic review and economic evaluation. / G. Norman [et al.]. //Health Technology Assessment. – 2013. – Vol. 17. – № 52. – P. 1-342.134.Oga, T. Comparison of the responsiveness of different generic health statusmeasures in patients with asthma / T. Oga [et al.] // Quality of Life Research. –2003. – № 5.
– P. 555-63.135.OrionGroup.[Электронныйресурс]//Режимдоступа:https://www.orion.fi/en/Orion-group / Загл. с экрана.136.Palen, J. Van Der. A randomised open-label cross-over study of inhalererrors, preference and time to achieve correct inhaler use in patients with COPD orasthma: Comparison of ELLIPTA with other inhaler devices / J.
Van Der Palen [etal.] // Prim. Care Respir. Med. – 2016. – Vol. 26. – № 9. – P. 1-8137.Polley, L. Impact of cough across different chronic respiratory diseases:comparison of two cough-specific health-related quality of life questionnaires. / L.Polley [et al.] // Chest. – 2008. – Vol. 134. – № 2.
– P. 295-302.138.Price, D. Effectiveness of same versus mixed asthma inhaler devices: Aretrospective observational study in primary care / D. Price [et al.] // Allergy,Asthma Immunol. Res. – 2012. – Vol. 4. – № 4. – P. 184-191.139.Rabe, K. Clinical management of asthma in 1999: the Asthma Insights andReality in Europe (AIRE) study / K. Rabe [et al.] // Allergy, Asthma Immunol. –2000. – Eur Respir J – № 5. – P. 802-807.187140.Randell, J. Safety of formoterol after cumulative dosing via Easyhaler® andAerolizer® / Randell J.
[et al.] // Respir. Med. 2005. – Vol. 99. – №12. – P. 1485-1493.141.Roche, N. Effectiveness of inhaler devices in adult asthma and COPD / N.Roche [et al.] // EMJ Respir. – 2013. – №10. – P. 64-71.142.Rodríguez-Martínez, C.E. Cost-utility analysis of the inhaled steroidsavailable in a developing country for the management of pediatric patients withpersistent asthma / C.E. Rodríguez-Martínez, M.P. Sossa-Briceño, J.A.
CastroRodriguez // J. Asthma. – 2013. – Vol. 50. -№ 4. – Vol. 410-418.143.Roggeri, A. Inhalation errors due to device switch in patients with chronic obstructivepulmonary disease and asthma: Critical health and economic issues / A. Roggeri, C.Micheletto, D.P.Roggeri // Int. J. COPD. – 2016. – Vol. 11. – №1. – P.
597-602.144.Saarni, S.I. The impact of 29 chronic conditions on health-related quality oflife: A general population survey in Finland using 15D and EQ-5D / S.I. Saarni [etal.] // Qual. Life Res. 2006. – Vol. 15. – № 8. – P. 1403-1414.145.Schulte, M. Handling of and Preferences for Available Dry Powder InhalerSystems by Patients with Asthma and COPD / S.I.
Saarni [et al.] // J. Aerosol Med.Pulm. Drug Deliv. – 2008. – Vol. 21. – №4. – P. 321-328.146.Schultz, A. Clinical Medicine Insights : Pediatrics Outpatient Management ofAsthma in Children / A. Schultz, A.C. Martin // J. Asthma. – 2006 – Vol.14 – P. 13-24.147.Schweisfurth, H. Comparison of two budesonide powder inhalers,Easyhaler® and Turbuhaler®, in steroid-naïve asthmatic patients / H.Schweisfurth[et al.]. // Respir. Med. – 2002. – Vol. 96.
– № 8. – P. 599-606.148.Sims, E.J. Current control and future risk in asthma management / E.J. Sims[et al.] // Allergy, Asthma Immunol. Res. – 2011. – Vol. 3. – №4. – P. 217-225.149.Small, M. Importance of inhaler-device satisfaction in asthma treatment: Real-world observations of physician-observed compliance and clinical/patient-reportedoutcomes / M. Small [et al.].
// Adv. Ther. – 2011. – Vol. 28. – №3. – P. 202-212.150.Szende, A. Psychometric and utility-based measures of health status ofasthmatic patients with different disease control level. / A. Szende [et al.] //Pharmacoeconomics. – 2004. – Vol. 22 – №8. – P. 537-547.188151.The Global Asthma Report – New Zealand: Global Asthma Network, 2018. – 92 p.152.The Global Impact of Respiratory Disease. / European Respiratory Society,2017. – 42 p.153.Thomas, M. Inhaled corticosteroids for asthma: impact of practice leveldevice switching on asthma control. / M.
Thomas [et al.] // BMC Pulm. Med. –2009. – Vol. 9. – P. 1.154.To, T. Global asthma prevalence in adults: Findings from the cross-sectional worldhealth survey / T. To [et al.]. // BMC Public Health. – 2012. – Vol. 12. – № 1. – P. 204.155.Tukiainen, H. Safety, tolerability and acceptability of two dry powderinhalers in the administration of budesonide in steroid-treated asthmatic patients /H. Tukiainen [et al.] // Respir. Med. 2002. – Vol. 96. – №4. – P.
221-229.156.Vanto, T. Comparison of two budesonide dry powder inhalers in thetreatment of asthma in children / T. Vanto [et al.] // J. aerosol Med. – 2004. – Vol.17. – № 1. – P. 15-24.157.Wang, H. Global, regional, and national life expectancy, all-cause mortality,and cause-specific mortality for 249 causes of death, 1980–2015: a systematicanalysis for the Global Burden of Disease Study 2015 / H. Wang [et al.] // Lancet.– 2016. – Vol. 388. – P.
1459-1544.158.WHO Collaborating Centre for Drug Statistics Methodology. WHOCC -ATC/DDDIndex[Электронныйресурс].URL:https://www.whocc.no/atc_ddd_index/ (дата обращения: 22.05.2018).159.Willems, D.C.M. Cost-effectiveness of a nurse-led telemonitoring intervention basedon peak expiratory flow measurements in asthmatics: Results of a randomised controlledtrial / D.C.M. Willems [et al.] // Cost Eff. Resour.
Alloc. – 2007. – Vol. 5. – P. 1-15.160.Wirl, C. Prevalence of asthma and allergies in children (Fact sheet No 3.1) /C. Wirl, V. Puklová // Eur. Environ. Heal. Inf. Syst. – 2007. – № 3.1. – 4 p.161.Wong, G.W. Factors associated with difference in prevalence of asthma inchildren from three cities in China: multicentre epidemiological survey / G.W.Wong [et al.] // BMJ. – 2004. – Vol. 329. – P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
